Everything You Need to Know About TATA 1mg Advertising — Costs, Formats, and How to Actually Get Results

Most brands that come to us asking about 1mg advertising have already spent weeks trying to piece together rate cards from scattered sources, only to find that the information available online is either outdated, vague, or written by someone who has clearly never actually booked a campaign on the platform. The reality is that TATA 1mg has quietly become one of the most powerful digital healthcare platforms in India, with a user base that skews toward exactly the kind of high-intent, health-conscious consumers that pharmaceutical brands, wellness companies, and even FMCG advertisers have been chasing for years. What makes this platform genuinely interesting from a media planning perspective is not just the scale — which is considerable — but the quality of the audience signal, which is something you simply cannot replicate on a general-purpose social media platform.

What Is 1mg Advertising and How Does It Work?

TATA 1mg started as a medicine information portal and evolved into a full-stack digital healthcare platform that now covers e-pharmacy, eDiagnostics, eConsultations, and subscription health plans under the Tata 1mg Care Plan umbrella. The advertising infrastructure built on top of this platform is, frankly speaking, more sophisticated than most people in the media planning world give it credit for. When a user opens the 1mg app to search for a diabetes medication, order a vitamin supplement, or book a lab test, they are generating intent data that is extraordinarily precise — and that data is what powers the 1mg advertising ecosystem.

The way 1mg advertising works is broadly similar to how retail media networks operate globally; brands can place display ads, sponsored listings, video ads, and push notifications across various touchpoints within the app and website, and the targeting is driven by a combination of search behaviour, purchase history, health condition categories, and demographic signals. What a lot of people miss is that this is not simply a banner-slapping exercise — the platform allows advertisers to reach users at specific moments in their health journey, which makes the purchase intent signal far stronger than what you would typically see on, say, a news website or a streaming platform. Our experience at SmartAds shows that campaigns run on TATA 1mg consistently outperform equivalent-budget campaigns on general display networks when the objective is conversion within the health and wellness category.

The platform was acquired by Tata Digital Ltd in 2021, which brought with it significant investment in technology infrastructure, and the advertising capabilities have expanded considerably since then. The Tata Business Excellence Group's operational rigour has also meant that the compliance and brand safety standards on the platform are considerably more structured than what you might encounter on smaller e-pharmacy platforms, which matters enormously for pharmaceutical brands that cannot afford to have their creative appearing alongside questionable content.

What Are the Different Ad Formats Available on TATA 1mg?

The range of ad formats on TATA 1mg is broader than most advertisers realise when they first approach the platform, and choosing the wrong format for your campaign objective is probably the single most common mistake we see brands make. The platform broadly supports banner ads, sponsored listings, video ads, push notifications, roadblock ads, article ads, and search result ads — each of which serves a different purpose in the funnel and carries a different cost structure.

Banner ads on 1mg appear across the homepage, category pages, and product pages, and they are the most commonly booked format simply because they are the most familiar. These display ads are available in standard dimensions and function on a CPM basis, meaning you are paying for cost per impression rather than for clicks; the CPM works out to roughly ₹150 to ₹300 depending on placement, audience targeting parameters, and the time of year, which is a number that surprises many first-time advertisers when they compare it to what they are paying for Instagram reach — though the comparison is not entirely fair because the audience quality and purchase intent on a digital healthcare platform are categorically different. Sponsored listings, on the other hand, are a bottom-funnel format that places your product at the top of search results and category pages when users are actively looking to buy; these typically operate on a CPC model, with click-through rates that are meaningfully higher than standard display because the user is already in purchase mode.

Video ads on TATA 1mg are a relatively newer addition to the format mix, and they include both non-skippable video ads that play within the app experience and longer-form content that can be embedded within article pages. Article ads — which are essentially branded content pieces placed within 1mg's health information section — are an underutilised format that we have found particularly effective for condition-awareness campaigns, where a brand wants to educate users about a health condition before introducing a product solution. Push notifications round out the format portfolio as a direct-to-user channel that, when used with restraint and proper audience segmentation, can deliver remarkably strong click-through rates; when overused, they are the fastest way to get your campaign flagged for user experience violations, which is something we have seen backfire when brands try to run high-frequency notification campaigns without proper frequency capping.

How Much Does It Cost to Advertise on 1mg? Rates, CPM, and CPC Benchmarks

This is the question that every client asks first, and the honest answer is that 1mg advertisement cost varies quite significantly based on format, targeting depth, campaign duration, and seasonality — but we can give you meaningful benchmarks that will help you build a realistic budget. The platform does not publish a universal rate card publicly, which is a source of frustration for media planners, but based on our experience booking campaigns across the platform, the numbers are in the following territory.

For standard banner ads running on a CPM basis, the cost per impression typically falls somewhere between ₹150 and ₹350 for run-of-platform placements, with premium homepage positions commanding rates closer to ₹400 to ₹600 CPM. Sponsored listings, which operate on a CPC model, generally see costs in the ballpark of ₹15 to ₹40 per click depending on category competitiveness — diabetes and cardiac categories tend to be more expensive because of higher advertiser demand, while niche wellness categories can be booked at the lower end of that range. Video ads carry a higher entry cost, with CPM rates for non-skippable video ads running somewhere between ₹400 and ₹700, which is actually competitive when you consider the captive attention you are getting from a user who is already engaged with health content. The minimum budget required to run a meaningful 1mg advertising campaign is generally in the range of ₹2 to ₹5 lakh for a month-long campaign, though roadblock formats and homepage takeovers require significantly larger commitments — typically upwards of ₹10 to ₹15 lakh for a single-day takeover.

What a lot of brands get wrong is comparing these 1mg ad rates directly to Google Display Network CPMs without accounting for the intent differential. A user on TATA 1mg who has just searched for "metformin alternatives" or "vitamin D deficiency symptoms" is in a completely different headspace from someone who sees your banner while reading general news; the conversion rate on 1mg campaigns we have managed has consistently been two to three times higher than equivalent display campaigns on general networks, which changes the return on investment calculation substantially. One pharmaceutical brand we worked with — a mid-sized OTC medicines company based out of Ahmedabad — shifted roughly 30% of their digital advertising budget from Google Display to TATA 1mg and saw their cost per acquisition drop by nearly 40% within the first quarter, which is the kind of data point that makes the conversation with the CFO considerably easier.

Who Should Advertise on 1mg — Pharma, Wellness, or FMCG Brands?

The instinctive answer is pharmaceutical brands, and yes, pharma advertising India has found a natural home on TATA 1mg — but the platform's utility extends considerably beyond prescription and OTC medicine brands. The user base of TATA 1mg skews toward urban, educated, health-conscious consumers between the ages of 25 and 55, which makes it an attractive advertising destination for a much wider set of categories than most media planners initially consider.

For pharmaceutical brands, the case for advertising on 1mg is almost self-evident; you are reaching users who are actively managing health conditions, researching medications, and making purchase decisions in your category. OTC medicines, nutraceuticals, and health supplements are particularly well-suited to the platform because users are already in a buying mindset and the path from ad exposure to purchase can be extremely short. FMCG advertising on 1mg makes sense for categories that have a clear health or wellness angle — think protein supplements, health foods, baby nutrition, and personal care products with a health positioning; a brand like Abbott Nutrition India, for instance, has a natural fit with the TATA 1mg audience in a way that a snack brand simply does not. Reckitt Benckiser has been among the early movers in this space, using the platform to promote their health and hygiene portfolio to an audience that is demonstrably more receptive to health messaging than the average Indian internet user.

The BFSI sector is a less obvious but genuinely interesting use case — health insurance brands and hospital chains have found TATA 1mg to be a high-quality top-funnel advertising environment because users on the platform are, by definition, thinking about their health, which creates a natural receptivity to health insurance messaging. We have also seen fitness equipment brands, diagnostic chains, and even some Tier 2 city hospital networks use the platform effectively for geo-targeted brand awareness campaigns. The honest caveat is that pure lifestyle FMCG brands without a credible health angle tend to see weaker performance on TATA 1mg compared to more contextually relevant categories, and we always advise clients to be honest about whether their brand genuinely belongs in a health context before committing budget to the platform.

What Targeting Options Does 1mg Offer Advertisers?

The audience targeting capabilities on TATA 1mg are, in our view, the most underappreciated aspect of the platform from an advertising standpoint. Because users create accounts, log their prescriptions, track their lab results, and search for specific health conditions, the platform sits on a first-party data asset that is genuinely rare in the Indian digital advertising landscape; this is not inferred interest data based on browsing patterns — it is declared health behaviour data, which is categorically more valuable for healthcare advertising.

Demographic targeting on TATA 1mg allows advertisers to segment by age, gender, and city — which covers the basics — but the more powerful options are the behavioural and contextual targeting layers. Behavioural targeting on the platform lets you reach users based on their purchase history, search behaviour, and health condition categories they have engaged with; you can, for instance, target users who have previously purchased diabetes-related products, which is a level of audience precision that a general digital advertising platform simply cannot match. Geo-targeting is available at the city and state level, which is particularly useful for regional brands or for national brands running city-specific campaigns; we have used this effectively for a diagnostic chain client in Bengaluru that wanted to drive lab test bookings specifically from users in South Bangalore, and the geo-targeted campaign delivered a cost per booking that was roughly 35% lower than their previous citywide campaigns.

Precision retargeting is another capability that deserves attention — users who have viewed a product page but not purchased can be retargeted with follow-up ads, which is a standard e-commerce capability but one that carries extra weight on a health platform because the consideration cycle for health products can be longer than for general consumer goods. Lookalike audience targeting, which allows you to reach new users whose behaviour resembles your existing customers, is available in more advanced campaign setups and is something we actively recommend for brands looking to scale beyond their existing customer base. At SmartAds, we always tell our clients that the targeting sophistication on TATA 1mg is only valuable if your creative strategy is built to match — a generic banner ad served to a precisely targeted audience is still a generic banner ad, and the platform's intelligence deserves creative that is equally specific.

How Do Roadblock Ads on TATA 1mg Differ from Banner Ads?

Roadblock ads are one of those formats that generate a lot of questions from clients who have heard the term but are not entirely sure what they are buying. A roadblock ad on TATA 1mg is essentially a homepage takeover — for a defined time window, typically a single day or a specific daypart, your brand owns all the prominent ad inventory on the platform's homepage, which means every user who opens the app during that window sees only your advertising. There is no competitive clutter, no other brand messages competing for attention; it is, in that sense, the digital equivalent of a full-page newspaper front cover wrap.

The practical difference from banner ads is significant in terms of both impact and cost. Standard banner ads are run-of-platform placements that appear alongside other advertisers' messages and are subject to frequency capping and audience targeting parameters; they are the right choice for sustained awareness campaigns, performance marketing objectives, and campaigns that need to run over weeks or months. Roadblock ads, by contrast, are a high-impact, short-duration format best suited for product launches, major brand moments, and seasonal campaigns where you want to create an unmissable presence — the kind of campaign where a consumer goods brand might want to own the entire health platform on World Diabetes Day or during flu season. The cost for a homepage takeover on TATA 1mg is, frankly speaking, not cheap; you are looking at investment in the range of ₹10 to ₹20 lakh for a single day, depending on the time of year and how far in advance you book, which is why this format is typically used by larger pharmaceutical brands and national FMCG players rather than smaller advertisers.

One automotive brand we worked with — which might seem like an odd fit for a health platform, but they were launching a campaign around "drive healthy, live healthy" — used a TATA 1mg roadblock on World Heart Day and achieved a brand recall lift that was measured at nearly double their benchmark from similar-format campaigns on other platforms; the contextual relevance of the message to the platform audience made the difference. Booking a roadblock requires advance planning of at least three to four weeks, and creative assets need to be submitted with enough lead time for compliance review, which is something we always flag to clients who are used to the faster turnaround times of programmatic display.

What Is the ROI of Advertising on 1mg Compared to Other Health Platforms?

Return on investment on TATA 1mg is a question that requires some nuance to answer properly, because the platform serves different objectives depending on where in the funnel you are operating and what category you are advertising in. What we can say with confidence, based on campaign data across multiple clients, is that TATA 1mg consistently delivers stronger ROI for bottom-funnel health and pharma campaigns than general-purpose digital platforms, and it competes favourably with other health-focused digital destinations when you factor in audience quality.

The platform's monthly active users are reported to be in the range of 40 million users, which places it among the largest digital healthcare platforms in India alongside PharmEasy and Apollo 24|7; but raw reach is only part of the story. The click-through rate on TATA 1mg sponsored listings typically runs somewhere between 2% and 5%, which is substantially higher than the industry average for display advertising in India — a number that the FICCI-EY Media Report and various digital advertising benchmarks consistently place below 1% for standard display. The conversion rate from click to purchase on sponsored product listings is also meaningfully higher than what you would see on a general marketplace, because the user has already demonstrated purchase intent through their search behaviour. For a nutraceuticals brand we managed a campaign for — a wellness products company targeting urban women between 30 and 50 — the sponsored listings campaign on TATA 1mg delivered a return on ad spend of roughly 4x over a three-month period, which compared favourably to their Google Shopping campaigns running simultaneously.

Brand lift and purchase intent metrics are harder to quantify but equally important for pharmaceutical brands that cannot sell directly online; for prescription medicine brands that are using TATA 1mg primarily for brand awareness rather than direct conversion, the platform's ability to reach users at the precise moment they are researching a health condition makes it one of the most efficient brand visibility investments available in Indian digital advertising. We have found that combining 1mg advertising with a parallel Google search campaign creates a measurable lift in branded search volume that neither channel achieves alone — a full-funnel effect that data-driven advertising strategies should account for when evaluating campaign performance.

What Are the Advertising Policies and Restrictions on 1mg?

This is a section that most agency pages skip over, which is a disservice to advertisers because getting your creative rejected after two weeks of production is an expensive and avoidable problem. TATA 1mg operates within a regulatory framework that is considerably more complex than general digital advertising, and the platform's advertising compliance requirements reflect both its own brand standards and the legal requirements that govern healthcare communications in India.

The foundational regulatory framework is the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, which prohibits advertising for prescription-only medicines to the general public and places strict restrictions on claims that can be made for any product in the health category; this is not a TATA 1mg-specific rule but a national law that applies to all advertising in India, and the platform enforces it rigorously. The Drugs and Cosmetics Act, 1940, and guidelines from the CDSCO (Central Drugs Standard Control Organisation) further define what can and cannot be claimed in healthcare advertising, and any creative submitted for a 1mg campaign must comply with these frameworks before it will be approved. In practical terms, this means that prescription medicines cannot be advertised to consumers on the platform, that OTC medicine ads cannot make therapeutic claims that go beyond what is approved on the product label, and that wellness products cannot make disease-cure claims without regulatory backing.

The 1mg advertising policy also has its own platform-specific restrictions around creative content — comparative advertising that names competitors, before-and-after imagery that implies guaranteed results, and testimonials from medical professionals that have not been properly disclosed are all categories of content that will be rejected. Our experience at SmartAds is that having a compliance-aware creative brief from the very beginning of the campaign process saves enormous amounts of time and money; we have seen campaigns delayed by three to four weeks because the creative team was not briefed on healthcare advertising regulations and produced assets that required fundamental reworking. The platform also restricts certain product categories entirely — tobacco products, alcohol, and certain categories of supplements that make unsubstantiated health claims are not eligible to advertise on 1mg regardless of how the creative is framed.

How Do You Book an Advertisement on TATA 1mg?

The booking process for 1mg advertising is something that no existing resource explains clearly, which is genuinely puzzling given how many brands are actively trying to figure it out. There are broadly two routes to advertising on TATA 1mg — direct booking through the platform's advertising team, and booking through an authorised media agency that has an established relationship with the platform.

The direct route involves reaching out to TATA 1mg's advertising sales team, which can be done through the platform's business contact channels; you will typically be assigned an account manager who will share a rate card, discuss your campaign objectives, and walk you through the available formats and targeting options. The process from initial contact to campaign launch generally takes somewhere between two and four weeks, depending on the complexity of the campaign and how quickly creative assets and compliance documentation can be submitted; for roadblock formats and homepage takeovers, the lead time is longer and availability windows need to be booked well in advance, particularly for high-demand periods like Diwali, flu season, or health awareness months. The minimum budget thresholds for direct bookings are generally higher than what you might achieve through an agency relationship, and the negotiating leverage for smaller advertisers is limited when dealing directly with the platform.

The agency route — which is, frankly speaking, what we recommend for most brands that are not running campaigns at a very large scale — gives you access to better rates, consolidated billing, and the benefit of a media planning team that knows which formats and targeting combinations actually deliver results rather than just what the platform's sales team is incentivised to sell. At SmartAds, we handle the entire process from brief to launch, including creative compliance review, audience targeting setup, campaign monitoring, and performance reporting; for brands that are new to the platform, this end-to-end management is particularly valuable because the learning curve on TATA 1mg is steeper than it looks from the outside. How to advertise on 1mg effectively is as much about knowing what not to do — which formats to avoid for which objectives, which targeting combinations are overpriced relative to their performance — as it is about knowing the mechanics of the booking process.

How Does 1mg Advertising Compare to PharmEasy and Netmeds Advertising?

The 1mg vs PharmEasy advertising comparison is one that comes up in almost every media planning conversation we have with health and pharma brands, and the honest answer is that they are not directly interchangeable — each platform has a distinct audience profile, a different advertising infrastructure, and a different strength in the funnel.

TATA 1mg has the broadest advertising format portfolio of the three major e-pharmacy platforms, with the most developed self-serve and managed advertising infrastructure; its monthly active users base of roughly 40 million users, combined with the depth of health intent data available for targeting, makes it the strongest platform for both brand awareness and performance marketing within the health category. PharmEasy has a comparable scale and is particularly strong in Tier 2 cities, where its distribution network and brand recognition have grown significantly; its advertising options are somewhat more limited in terms of format variety, but the CPM rates are generally lower, which makes it an interesting option for advertisers who are more focused on reach efficiency than on targeting precision. Netmeds, which operates under the Reliance Retail umbrella, has a strong presence in South India and benefits from the Reliance ecosystem's data infrastructure; its advertising capabilities are less developed than TATA 1mg's but its audience skew toward South Indian cities makes it a useful complementary platform for brands with strong regional presence in markets like Chennai, Hyderabad, and Bengaluru.

What we typically recommend to clients is not an either-or choice but a portfolio approach — using TATA 1mg as the primary platform for its superior targeting and format options, supplemented by PharmEasy for incremental reach in Tier 2 cities and Netmeds for South India-specific campaigns. The CPM rates on TATA 1mg are generally 15% to 25% higher than on PharmEasy for comparable placements, but the click-through rate and conversion rate differential more than justifies the premium in most categories we have tested. Apollo 24|7 and Practo are also worth considering in the broader health platform advertising ecosystem, particularly for brands targeting users who are in an active doctor consultation or diagnostics journey rather than a purchase journey.

What Metrics Should You Track for Your 1mg Ad Campaign?

Campaign performance measurement on TATA 1mg is an area where we see a lot of brands either over-engineering their reporting or, more commonly, tracking the wrong metrics entirely and drawing incorrect conclusions about whether the campaign is working. The right metrics depend entirely on your campaign objective, which sounds obvious but is a distinction that gets lost surprisingly often in the rush to pull dashboard numbers.

For brand awareness campaigns — which are typically run using display ads and video ads on a CPM basis — the primary metrics to track are impressions delivered, unique reach, frequency, and brand lift measured through pre- and post-campaign surveys; click-through rate is a secondary metric for awareness campaigns and should not be used as the primary success indicator, because a low CTR on a brand awareness campaign does not mean the campaign is not working. For performance marketing campaigns using sponsored listings and CPC formats, the metrics that matter are click-through rate, conversion rate, cost per click, and ultimately return on ad spend or cost per acquisition; TATA 1mg's reporting dashboard provides these metrics in real time, and the platform also offers integration with third-party analytics tools for advertisers who want to track the full customer journey beyond the click. Purchase intent lift, which measures the increase in the proportion of users who say they intend to purchase your brand after seeing the campaign, is a metric that requires dedicated research but is particularly valuable for pharmaceutical brands where direct conversion tracking is not always possible.

One nuance that we always flag to clients is the attribution question — TATA 1mg advertising often contributes to conversions that are ultimately completed on the brand's own website, on Google, or in a physical pharmacy, and these conversions will not show up in the platform's own attribution reporting. The GroupM TYNY Report and various digital marketing studies have consistently highlighted this cross-channel attribution challenge in Indian digital advertising; the solution is to use a combination of platform reporting, branded search volume tracking, and periodic geo-lift studies — which Google has partnered with TATA 1mg to conduct for some larger advertisers — to build a more complete picture of the campaign's true impact on business outcomes.

How Can Brands Maximize Results from 1mg Sponsored Listings?

Sponsored listings on 1mg are the format that delivers the most direct and measurable return on investment for brands that are selling products available on the platform, and yet they are consistently underutilised relative to their potential because most advertisers do not think carefully enough about the optimisation levers available to them. The basic mechanic is straightforward — your product appears at the top of relevant search results and category pages — but the difference between a well-optimised sponsored listing campaign and a poorly managed one can be the difference between a 2x and a 5x return on ad spend.

The first lever is keyword strategy; TATA 1mg's sponsored listings operate on a search intent model, which means your bids need to be matched to the specific search terms your target customers are using on the platform. Generic category terms like "vitamin C tablets" will be more expensive and more competitive than specific product-adjacent terms like "immunity booster for adults" or "vitamin C with zinc"; the brands that get the most out of 1mg sponsored products are the ones that invest time in understanding the platform's search vocabulary, which is different from Google search vocabulary because the user is already on a health platform and tends to use more specific, product-oriented search terms. The second lever is product page quality — a sponsored listing drives traffic to your product page, and if that page has poor imagery, incomplete descriptions, or few reviews, the conversion rate will be low regardless of how well-targeted the ad is; we always audit our clients' product pages on TATA 1mg before launching a sponsored listings campaign, because sending paid traffic to an underperforming page is a waste of advertising budget.

Seasonal timing is the third lever that most brands underutilise; the demand for specific product categories on TATA 1mg spikes predictably around certain periods — vitamin D and immunity products see significant volume increases in the October to February period, anti-allergy products peak during the monsoon, and digestive health products see elevated search volumes around festival seasons when dietary patterns change. A wellness products brand we worked with in Mumbai doubled their sponsored listings budget during the monsoon season for their anti-allergy portfolio and achieved a cost per acquisition that was roughly 45% lower than their annual average, simply because they were investing at a time when organic demand was already elevated and the conversion probability was higher.

FAQ: Your 1mg Advertising Questions Answered

Q: How much does it cost to advertise on TATA 1mg in India?

The 1mg advertisement cost varies by format and targeting, but as a practical benchmark, standard banner ads run on a CPM basis in the range of roughly ₹150 to ₹350 for run-of-platform placements, with premium homepage positions going higher. Sponsored listings on a CPC model typically cost somewhere between ₹15 and ₹40 per click depending on category competitiveness. Video ads carry CPM rates in the ballpark of ₹400 to ₹700, while roadblock formats and homepage takeovers require investments upward of ₹10 to ₹15 lakh for a single day. These are working benchmarks based on our campaign experience and should be treated as directional rather than fixed, since rates are negotiated and vary with seasonality, campaign volume, and advance booking.

Q: What types of ads can I run on the 1mg platform?

TATA 1mg supports a range of digital advertising formats including banner ads, sponsored listings, video ads (both non-skippable video ads and longer-form content), push notifications, roadblock ads, article ads, search result ads, and product page ads. Each format serves a different objective in the funnel — sponsored listings are best for direct conversion, banner ads and video ads for brand awareness, and push notifications for re-engagement with existing users. The platform also offers homepage takeover packages that combine multiple format placements into a single high-impact buy.

Q: What is the minimum budget required for a 1mg advertising campaign?

Based on our experience booking campaigns on the platform, the practical minimum for a meaningful month-long 1mg advertising campaign is in the range of ₹2 to ₹5 lakh, which is sufficient to run a focused sponsored listings or banner ad campaign with reasonable audience targeting. Below this threshold, the reach and frequency are generally too limited to draw meaningful conclusions about campaign performance. For roadblock formats and homepage takeovers, the minimum commitment is considerably higher, typically starting at ₹10 lakh for a single day. Brands with smaller budgets are often better served by starting with sponsored listings, which offer more precise cost control on a CPC basis.

Q: How do I book an advertisement on TATA 1mg?

There are two primary routes — direct booking through TATA 1mg's advertising sales team, or booking through an authorised media agency. The direct route involves contacting the platform's business team, receiving a rate card, submitting creative assets and compliance documentation, and going through an internal review process before the campaign goes live; the typical timeline from first contact to launch is two to four weeks. The agency route is generally faster and offers better rates for advertisers who are not operating at very large scale, with the added benefit of media planning expertise and compliance support. Either way, advance booking of at least three to four weeks is recommended, and longer for premium formats.

Q: What industries or product categories are eligible to advertise on 1mg?

OTC medicines, nutraceuticals, health supplements, wellness products, diagnostic services, health insurance, hospital chains, fitness products, baby nutrition, and health-positioned personal care products are all eligible to advertise on TATA 1mg. FMCG advertising is permitted for categories with a credible health or wellness angle. Prescription medicines cannot be advertised to consumers under the Drugs and Magic Remedies Act. Tobacco, alcohol, and products making unsubstantiated health claims are not eligible. The platform's compliance team reviews all creative before approval, and categories with regulatory complexity — such as medical devices and certain supplement categories — may require additional documentation.

Q: Are prescription medicines allowed to be advertised on 1mg?

No — prescription medicines cannot be advertised to the general public on TATA 1mg or any other consumer-facing platform in India, as this is prohibited under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. Pharmaceutical brands with prescription medicine portfolios can, however, use the platform for disease awareness campaigns that educate users about health conditions without promoting specific prescription products, which is a legitimate and effective use of the platform's high-intent audience. Any advertising in the health and pharma category must comply with CDSCO guidelines and the Drugs and Cosmetics Act, 1940, and the platform enforces these requirements through its creative review process.

Q: What is a roadblock ad on 1mg and how is it different from a banner ad?

A roadblock ad on TATA 1mg is a homepage takeover format where a single advertiser owns all prominent ad inventory on the platform's homepage for a defined time window — typically a full day or a specific daypart — creating an exclusive brand presence with no competitive clutter. This is fundamentally different from a standard banner ad, which is a run-of-platform placement that appears alongside other advertisers' messages and is subject to audience targeting and frequency parameters. Roadblock ads are a high-impact, high-cost format suited for product launches and major brand moments; banner ads are the right choice for sustained, cost-efficient awareness and performance campaigns over longer durations.

Q: How does 1mg advertising target specific audiences in India?

TATA 1mg offers demographic targeting by age, gender, and location; behavioural targeting based on purchase history, search behaviour, and health condition categories; geo-targeting at the city and state level; and precision retargeting for users who have previously engaged with specific product pages. The platform's first-party data — derived from users' declared health behaviour, prescription history, and lab results — gives it a targeting advantage over general digital advertising platforms. Geo-targeting is available down to the city level, which is useful for regional campaigns; we have used this effectively for clients targeting specific cities like Bengaluru, Mumbai, and Delhi with tailored messaging.

Q: What is the reach and monthly active user base of TATA 1mg?

TATA 1mg has a reported monthly active users base of approximately 40 million users, making it one of the largest digital healthcare platforms in India. The user base skews toward urban, educated, health-conscious consumers between 25 and 55, with strong representation in metros like Mumbai, Delhi, Bengaluru, and Gurugram as well as growing penetration in Tier 2 cities. The platform's reach extends across PAN India, with the app available in 500+ cities and the website accessible nationally. This scale, combined with the health intent quality of the audience, makes it a significant advertising destination for brands in the health, pharma, and wellness categories.

Q: How do I measure the ROI of my 1mg advertising campaign?

ROI measurement on TATA 1mg depends on your campaign objective. For performance campaigns using sponsored listings and CPC formats, the platform's dashboard provides real-time data on click-through rate, conversion rate, cost per click, and return on ad spend. For brand awareness campaigns, brand lift studies and purchase intent surveys conducted pre- and post-campaign provide the most meaningful measurement. Cross-channel attribution — tracking how 1mg advertising contributes to conversions completed on other platforms — requires a combination of platform reporting, branded search volume monitoring, and geo-lift studies. We recommend setting up measurement frameworks before the campaign launches rather than trying to reconstruct attribution after the fact.

Q: How does advertising on 1mg compare to advertising on PharmEasy or Netmeds?

TATA 1mg has the most developed advertising infrastructure of the three major e-pharmacy platforms, with the broadest format portfolio and the most sophisticated audience targeting capabilities. PharmEasy offers comparable reach at generally lower CPM rates and is particularly strong in Tier 2 cities; its advertising options are more limited in format variety. Netmeds has a strong South India presence and benefits from the Reliance ecosystem